Updated BHIVA-BASHH Position Statement on PrEP in the UK Recent results from clinical trials of PrEP have made it clear that this biomedical prevention tool could have a major impact on the HIV epidemic in the UK. The intention of this updated Position Statement is to inform UK healthcare workers on the role of antiretroviral pre-exposure prophylaxis (PrEP) in the setting of the UK epidemic, so that they can have an informed discussion with their patients.
The evidence gathered in our own epidemic setting for the benefits of PrEP for the individual, and for the health service, is compelling. Further, it offers an opportunity to engage with those most at risk of HIV, buying time for a sustainable change in behaviour and averting a condition that requires life-long therapy. The HIV incidence observed in PROUD and IPERGAY is unacceptably high, and existing prevention strategies are clearly insufficient. Our recommendation is that PrEP should be made available to the most at-risk populations.
BHIVA welcomes the provisional results of the START study BHIVA welcomes the provisional results of the START study, which demonstrate significant benefits to starting antiretroviral therapy early. We look forward to the presentation of the full results at the IAS conference in Vancouver in July.
HIV: A guide for police forces "HIV: A guide for police forces" is endorsed by BHIVA and includes information about how to address HIV in police occupational health policies and blood-borne virus (BBV) training.
HIV Partner Notification: a missed opportunity? This NAT report highlights the importance of partner notification and steps that need to be taken at a local and national level in order to ensure high quality, consistent and cost-effective HIV partner notification in the UK.